Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.

The introduction of novel therapies for gynecologic malignancies such as immunotherapy, SBRT and complex brachytherapy can lead to increased frequency of severe toxicities for which treatment options may be limited.

This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a business fundamentals review and a radiopharmaceuticals overview.

Lung cancer screening is resulting in a higher incidence of early-stage lung cancer diagnoses. This commonly occurs among older patients with chronic lung disease who are at high risk for complications with attaining pathologic confirmation.

The management of Hepatocellular Carcinoma (HCC) should be conducted in a multidisciplinary setting to offer individualized therapy. Most patients with HCC are not candidates for curative treatments because of tumor extent or underlying liver dysfunction.

MRI-guided Radiation Therapy (MRgRT), FLASH proton therapy, concurrent immunotherapy, and radiation therapy and SBRT for oligometastatic disease, are emerging technologies and approaches to optimize cancer care.

SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone.

HyTEC (Hypo-fractionated or “Hy”-dose per fraction, Treatment Effects in the Clinic) was an American Association of Physicists in Medicine-led initiative focusing on hypofractionated SBRT/SABR and stereotactic radiosurgery in adults.

The field of cancer is a rapidly evolving field with new treatment approaches moving to clinic on a daily basis. Radiation Oncology is no different. It is extremely difficult for a practicing clinician to stay abreast of new developments in cancer care.

The associated article is a meta-analysis reviewing published studies for SBRT for HCC with 5+ years of outcome data. 19 studies were identified that met the criteria. The article reviews those 19 studies and makes recommendations for appropriate SBRT for HCC.